Á¦10ȸ »ï¼º¾È°ú ½ÉÆ÷Áö¾ö(³ì³»Àå) : 2023-07-08
±³À°ÀÏÀÚ : 2023-07-08
±³À°Àå¼Ò : »ï¼º¼¿ïº´¿ø ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç
±³À°ÁÖÁ¦ : Á¦10ȸ »ï¼º¾È°ú ½ÉÆ÷Áö¾ö(³ì³»Àå)
ÁÖÃÖ±â°ü : »ï¼º¼¿ïº´¿ø
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¾È°ú
´ã´çÀÚ : ¹Ú¹Ì³ª
¿¬¶ôó : 02-3410-3569
À̸ÞÀÏ : minasun.park@samsung.com
±³À°Á¾·ù : ÀÇ»çÇÐ
Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 25ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 08:55~09:00 °³È¸»ç ÇÔµ·ÀÏ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 09:00~09:10 Anatomy in glaucoma ÀÌÀºÁ¤(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 09:10~09:20 Molecular biology in glaucoma Á¶Çö°æ(°æ»óÀÇ´ë)
±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 09:20~09:30 Pathophysiology in glaucoma ±è¿µ±¹(¼¿ïÀÇ´ë)
±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 09:30~09:40 Animal models in glaucoma ³ë½Â¼ö(Â÷ÀÇ°úÇдë)
±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 09:40~09:50 Lymphatics and glaucoma ¹Úµµ¿µ(¼º±Õ°üÀÇ´ë)
Åä·Ð 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 09:50~10:10 Discussion ( )
ÈÞ½Ä 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 10:10~10:25 Coffee Break ( )
±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 10:25~10:35 Myopia: How does it affect glaucoma? ±è¸¶¸£´Ù(µ¿±¹ÀÇ´ë)
±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 10:35~10:45 Optic disc morphology: Does It predict the future VF defect pattern? ÇÑÁ¾Ã¶(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 10:45~10:55 FDT & 10-2 VF: Do they offer additional information? Á¤°æÀÎ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 10:55~11:05 AngioOCT: The tips how to use AngioOCT in glaucoma clinic ¼¹ÎÈñ(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 11:05~11:15 ICP: The influence of CSF pressure in glaucoma ±è°íÀº(¿ï»êÀÇ´ë)
Åä·Ð 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 11:15~11:35 Discussion ( )
±âŸ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 11:35~12:05 Special Session :³ì³»Àå°ú ÇÔ²²ÇÑ 30¿©³â ±ââ¿ø(¼º±Õ°üÀÇ´ë)
½Ä»ç 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ǪµåÄÚÆ® 12:05~13:30 LUNCH ( )
±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 13:30~13:40 Congenital glaucoma ¼¿ï(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 13:40~13:50 Traumatic glaucoma ÀÌ°æ¹Î(¼¿ïÀÇ´ë)
±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 13:50~14:00 Uveitic glaucoma ÃÖÁø¾Æ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 14:00~14:10 Pseudoexfoliative glaucoma ±èÁ¤¸²(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 14:10~14:20 Neovascular glaucoma ÀÌÁö¿õ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 14:20~14:30 Malignant glaucoma ÀÌÅÂÀº(ÀüºÏÀÇ´ë)
Åä·Ð 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 14:30~14:50 Discussion ( )
ÈÞ½Ä 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 14:50~15:05 Coffee Break ( )
±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 15:05~15:20 How to interpret the measured IOP in clinic when we consider the diurnal variation of IOP À¯Á¤±Ç(°í·ÁÀÇ´ë)
±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 15:20~15:35 How to determine the progression when we meet glaucoma patients with VF progression but without ONH change. ¹èÇü¿ø(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 15:35~15:50 Targeting IOP: What should we do when we meet persistent progression of glaucoma patients with low teen IOP? ÀÌÀºÁö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 15:50~16:05 Why are there many NTG patients in Asian population? Á¤Áø¿í(¼¿ïÀÇ´ë)
±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 16:05~16:20 Strategies for neuroprotection: Which should be the main target – ganglion cell, axon, or glial cell? ¹ÚÇý¿µ(°¡Å縯ÀÇ´ë)
Åä·Ð 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 16:20~16:50 Discussion ( )
±âŸ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°´ç 16:50~16:55 Æóȸ»ç ( )